peter attia bpc-157 BPC157 and Anti-Aging Insights with 387 - AMA #83: Peptides—evaluating

doi: 10.1016/j.biocel.2020.105802

Chapter references The content in the Pharmacokinetics section is based on the ebook, Basic Pharmacokinetics by Bourne.

However, the absence of formal clinical trials means long-term safety cannot be guaranteed

Concerns have been raised about serious side effects (e.g., gastrointestinal paralysis)

Originally engineered at Washington State University by the Harding lab and later licensed to M3 Biotechnology, Dihexa retains the angiotensin IV pharmacophore for AT4 receptor binding while incorporating N-hexanoyl and aminohexanoic acid modifications that confer metabolic stability and lipophilic BBB penetration